Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax...

Full description

Saved in:
Bibliographic Details
Published inJournal of hematology and oncology Vol. 14; no. 1; pp. 1 - 8
Main Authors Wang, Michael, Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P., Eliadis, Paul, Peyrade, Frédéric, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K., Tam, Constantine S.
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 30.10.2021
BioMed Central
BMC
Subjects
Antimitotic agents
Antineoplastic agents
Apoptosis
Blood
Blood cancer
Bone marrow
Cardiac arrhythmia
Creatinine
Development and progression
Hematological cancers/lymphomas
Hematology
Ibrutinib
Inhibitor drugs
Laboratories
Leukemia
Lymphoma
Lysis
Mantle cell lymphoma
Neutropenia
Non-Hodgkin's lymphomas
Oncology
Patients
Potassium
Rapid Communication
Safety
Safety and security measures
Small molecule agents/kinase inhibitors
Targeted cancer therapy
Tumors
Venetoclax
United States > US
Online AccessGet full text

Cover

Abstract Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL. A safety run-in (SRI) cohort was conducted to inform whether an ibrutinib lead-in should be implemented for the randomized portion. Patients received concurrent ibrutinib 560 mg continuously plus venetoclax in a 5-week ramp-up to venetoclax 400 mg for up to 2 years. The primary endpoint was occurrence of tumor lysis syndrome (TLS) and dose-limiting toxicities (DLTs). The SRI cohort enrolled 21 patients; six and 15 were in low- or increased-risk categories for TLS, respectively. During the 5-week venetoclax ramp-up, three patients had DLTs, and one patient at increased risk for TLS had a laboratory TLS; no additional TLS events occurred during follow-up. With a median follow-up of 31 months, the overall response rate was 81% (17/21); 62% (13/21) of patients had a complete response. SRI data informed that the randomized portion should proceed with concurrent ibrutinib plus venetoclax, with no ibrutinib lead-in. Ibrutinib plus venetoclax demonstrated promising efficacy; no new safety signals were observed. Trial registration : ClinicalTrials.gov, NCT03112174. Registered 13 April 2017, https://clinicaltrials.gov/ct2/show/NCT03112174 .
AbstractList Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL. A safety run-in (SRI) cohort was conducted to inform whether an ibrutinib lead-in should be implemented for the randomized portion. Patients received concurrent ibrutinib 560 mg continuously plus venetoclax in a 5-week ramp-up to venetoclax 400 mg for up to 2 years. The primary endpoint was occurrence of tumor lysis syndrome (TLS) and dose-limiting toxicities (DLTs). The SRI cohort enrolled 21 patients; six and 15 were in low- or increased-risk categories for TLS, respectively. During the 5-week venetoclax ramp-up, three patients had DLTs, and one patient at increased risk for TLS had a laboratory TLS; no additional TLS events occurred during follow-up. With a median follow-up of 31 months, the overall response rate was 81% (17/21); 62% (13/21) of patients had a complete response. SRI data informed that the randomized portion should proceed with concurrent ibrutinib plus venetoclax, with no ibrutinib lead-in. Ibrutinib plus venetoclax demonstrated promising efficacy; no new safety signals were observed. Trial registration : ClinicalTrials.gov, NCT03112174. Registered 13 April 2017, https://clinicaltrials.gov/ct2/show/NCT03112174 .
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL. A safety run-in (SRI) cohort was conducted to inform whether an ibrutinib lead-in should be implemented for the randomized portion. Patients received concurrent ibrutinib 560 mg continuously plus venetoclax in a 5-week ramp-up to venetoclax 400 mg for up to 2 years. The primary endpoint was occurrence of tumor lysis syndrome (TLS) and dose-limiting toxicities (DLTs). The SRI cohort enrolled 21 patients; six and 15 were in low- or increased-risk categories for TLS, respectively. During the 5-week venetoclax ramp-up, three patients had DLTs, and one patient at increased risk for TLS had a laboratory TLS; no additional TLS events occurred during follow-up. With a median follow-up of 31 months, the overall response rate was 81% (17/21); 62% (13/21) of patients had a complete response. SRI data informed that the randomized portion should proceed with concurrent ibrutinib plus venetoclax, with no ibrutinib lead-in. Ibrutinib plus venetoclax demonstrated promising efficacy; no new safety signals were observed. Trial registration: ClinicalTrials.gov, NCT03112174. Registered 13 April 2017, https://clinicaltrials.gov/ct2/show/NCT03112174.
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL. A safety run-in (SRI) cohort was conducted to inform whether an ibrutinib lead-in should be implemented for the randomized portion. Patients received concurrent ibrutinib 560 mg continuously plus venetoclax in a 5-week ramp-up to venetoclax 400 mg for up to 2 years. The primary endpoint was occurrence of tumor lysis syndrome (TLS) and dose-limiting toxicities (DLTs). The SRI cohort enrolled 21 patients; six and 15 were in low- or increased-risk categories for TLS, respectively. During the 5-week venetoclax ramp-up, three patients had DLTs, and one patient at increased risk for TLS had a laboratory TLS; no additional TLS events occurred during follow-up. With a median follow-up of 31 months, the overall response rate was 81% (17/21); 62% (13/21) of patients had a complete response. SRI data informed that the randomized portion should proceed with concurrent ibrutinib plus venetoclax, with no ibrutinib lead-in. Ibrutinib plus venetoclax demonstrated promising efficacy; no new safety signals were observed.Trial registration: ClinicalTrials.gov, NCT03112174. Registered 13 April 2017, https://clinicaltrials.gov/ct2/show/NCT03112174 .Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL. A safety run-in (SRI) cohort was conducted to inform whether an ibrutinib lead-in should be implemented for the randomized portion. Patients received concurrent ibrutinib 560 mg continuously plus venetoclax in a 5-week ramp-up to venetoclax 400 mg for up to 2 years. The primary endpoint was occurrence of tumor lysis syndrome (TLS) and dose-limiting toxicities (DLTs). The SRI cohort enrolled 21 patients; six and 15 were in low- or increased-risk categories for TLS, respectively. During the 5-week venetoclax ramp-up, three patients had DLTs, and one patient at increased risk for TLS had a laboratory TLS; no additional TLS events occurred during follow-up. With a median follow-up of 31 months, the overall response rate was 81% (17/21); 62% (13/21) of patients had a complete response. SRI data informed that the randomized portion should proceed with concurrent ibrutinib plus venetoclax, with no ibrutinib lead-in. Ibrutinib plus venetoclax demonstrated promising efficacy; no new safety signals were observed.Trial registration: ClinicalTrials.gov, NCT03112174. Registered 13 April 2017, https://clinicaltrials.gov/ct2/show/NCT03112174 .
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL. A safety run-in (SRI) cohort was conducted to inform whether an ibrutinib lead-in should be implemented for the randomized portion. Patients received concurrent ibrutinib 560 mg continuously plus venetoclax in a 5-week ramp-up to venetoclax 400 mg for up to 2 years. The primary endpoint was occurrence of tumor lysis syndrome (TLS) and dose-limiting toxicities (DLTs). The SRI cohort enrolled 21 patients; six and 15 were in low- or increased-risk categories for TLS, respectively. During the 5-week venetoclax ramp-up, three patients had DLTs, and one patient at increased risk for TLS had a laboratory TLS; no additional TLS events occurred during follow-up. With a median follow-up of 31 months, the overall response rate was 81% (17/21); 62% (13/21) of patients had a complete response. SRI data informed that the randomized portion should proceed with concurrent ibrutinib plus venetoclax, with no ibrutinib lead-in. Ibrutinib plus venetoclax demonstrated promising efficacy; no new safety signals were observed. Trial registration: ClinicalTrials.gov, NCT03112174. Registered 13 April 2017, Keywords: Hematological cancers/lymphomas, Small molecule agents/kinase inhibitors, Ibrutinib, Venetoclax, Safety
Abstract Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL. A safety run-in (SRI) cohort was conducted to inform whether an ibrutinib lead-in should be implemented for the randomized portion. Patients received concurrent ibrutinib 560 mg continuously plus venetoclax in a 5-week ramp-up to venetoclax 400 mg for up to 2 years. The primary endpoint was occurrence of tumor lysis syndrome (TLS) and dose-limiting toxicities (DLTs). The SRI cohort enrolled 21 patients; six and 15 were in low- or increased-risk categories for TLS, respectively. During the 5-week venetoclax ramp-up, three patients had DLTs, and one patient at increased risk for TLS had a laboratory TLS; no additional TLS events occurred during follow-up. With a median follow-up of 31 months, the overall response rate was 81% (17/21); 62% (13/21) of patients had a complete response. SRI data informed that the randomized portion should proceed with concurrent ibrutinib plus venetoclax, with no ibrutinib lead-in. Ibrutinib plus venetoclax demonstrated promising efficacy; no new safety signals were observed. Trial registration: ClinicalTrials.gov, NCT03112174. Registered 13 April 2017, https://clinicaltrials.gov/ct2/show/NCT03112174 .
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL. A safety run-in (SRI) cohort was conducted to inform whether an ibrutinib lead-in should be implemented for the randomized portion. Patients received concurrent ibrutinib 560 mg continuously plus venetoclax in a 5-week ramp-up to venetoclax 400 mg for up to 2 years. The primary endpoint was occurrence of tumor lysis syndrome (TLS) and dose-limiting toxicities (DLTs). The SRI cohort enrolled 21 patients; six and 15 were in low- or increased-risk categories for TLS, respectively. During the 5-week venetoclax ramp-up, three patients had DLTs, and one patient at increased risk for TLS had a laboratory TLS; no additional TLS events occurred during follow-up. With a median follow-up of 31 months, the overall response rate was 81% (17/21); 62% (13/21) of patients had a complete response. SRI data informed that the randomized portion should proceed with concurrent ibrutinib plus venetoclax, with no ibrutinib lead-in. Ibrutinib plus venetoclax demonstrated promising efficacy; no new safety signals were observed.
ArticleNumber 179
Audience Academic
Author Ramchandren, Radhakrishnan
Neuenburg, Jutta K.
Eckert, Karl
Karlin, Lionel
Wu, Ka Lung
Lee, Yihua
Jurczak, Wojciech
Eliadis, Paul
Wang, Michael
Chong, Geoffrey
Tam, Constantine S.
Collins, Graham P.
Peyrade, Frédéric
Bishton, Mark
Chen, Robert
Author_xml – sequence: 1
  givenname: Michael
  orcidid: 0000-0001-9748-5486
  surname: Wang
  fullname: Wang, Michael
– sequence: 2
  givenname: Radhakrishnan
  surname: Ramchandren
  fullname: Ramchandren, Radhakrishnan
– sequence: 3
  givenname: Robert
  surname: Chen
  fullname: Chen, Robert
– sequence: 4
  givenname: Lionel
  surname: Karlin
  fullname: Karlin, Lionel
– sequence: 5
  givenname: Geoffrey
  surname: Chong
  fullname: Chong, Geoffrey
– sequence: 6
  givenname: Wojciech
  surname: Jurczak
  fullname: Jurczak, Wojciech
– sequence: 7
  givenname: Ka Lung
  surname: Wu
  fullname: Wu, Ka Lung
– sequence: 8
  givenname: Mark
  surname: Bishton
  fullname: Bishton, Mark
– sequence: 9
  givenname: Graham P.
  surname: Collins
  fullname: Collins, Graham P.
– sequence: 10
  givenname: Paul
  surname: Eliadis
  fullname: Eliadis, Paul
– sequence: 11
  givenname: Frédéric
  surname: Peyrade
  fullname: Peyrade, Frédéric
– sequence: 12
  givenname: Yihua
  surname: Lee
  fullname: Lee, Yihua
– sequence: 13
  givenname: Karl
  surname: Eckert
  fullname: Eckert, Karl
– sequence: 14
  givenname: Jutta K.
  surname: Neuenburg
  fullname: Neuenburg, Jutta K.
– sequence: 15
  givenname: Constantine S.
  surname: Tam
  fullname: Tam, Constantine S.
BookMark eNp9kktr3DAUhU1JaR7tH-hKUCjZONHDkuwuCsPQRyAlhaaLroRsX2cUZGkqySGz7S-vPJPSTChFC4mr75wrXc5xceC8g6J4TfAZIbU4j4ThipeYkhLnQl3ePyuOiOSirCWlB4_Oh8VxjLcYC9JQ_KI4ZJUkUjT0qPi19K6bQgCXkGnDlIwzLVrbKaI7cJB8Z_U9Mg4FsHodoT8PMATdJR82aNQuWUAdWIvsZlyv_KjfobQCFPUAaYPC5Mqs9cO2uF7pCIihbz--fF1cXyyvUExTv3lZPB-0jfDqYT8pvn_8cL38XF5efbpYLi7LjkuSyp43A9UV1ljzpsKyorLtK0qEgKptgXNNyIAZY5Rj2fQNk0NLQRBGWUU6CuykuNj59l7fqnUwow4b5bVR24IPN0qHZDoLimtGW0lEJXtZCd40DRuGhtBaAq-h5tnr_c5rPbUj9F0eX9B2z3T_xpmVuvF3quZcNHI2OH0wCP7nBDGp0cR5kNqBn6KiPLcjmAuW0TdP0Fs_BZdHNVN1fhwh_C91o_MHjBt87tvNpmohaiI4lYxk6uwfVF49jKbL8RpMru8J3j4SrEDbtIre5px4F_fBegd2wceYQ6I6k_SM5Q7GKoLVHFq1C63KoVXb0Kr7LKVPpH_m-B_Rb0327WQ
CitedBy_id crossref_primary_10_1186_s40364_022_00357_5
crossref_primary_10_7759_cureus_36305
crossref_primary_10_1186_s13045_023_01496_4
crossref_primary_10_3238_PersOnko_2024_02_09_06
crossref_primary_10_1182_bloodadvances_2023012424
crossref_primary_10_3389_fonc_2023_1098326
crossref_primary_10_1136_bcr_2022_249631
crossref_primary_10_1182_blood_2023022420
crossref_primary_10_1111_bjh_18697
crossref_primary_10_1016_j_eclinm_2023_102221
crossref_primary_10_1080_10428194_2023_2264430
crossref_primary_10_35754_0234_5730_2022_67_3_441_452
crossref_primary_10_1080_10428194_2023_2283393
crossref_primary_10_1007_s11912_022_01286_0
crossref_primary_10_1007_s11523_021_00857_8
crossref_primary_10_1080_17474086_2024_2427663
crossref_primary_10_3390_ijms25020766
crossref_primary_10_1007_s12672_024_01161_3
crossref_primary_10_3324_haematol_2022_282031
crossref_primary_10_1038_s41408_023_00799_6
crossref_primary_10_1186_s40164_022_00283_0
crossref_primary_10_1182_blood_2023022351
crossref_primary_10_3324_haematol_2022_281668
crossref_primary_10_3390_cancers14246026
crossref_primary_10_1016_j_bneo_2024_100034
crossref_primary_10_1186_s13045_022_01353_w
crossref_primary_10_1080_14740338_2024_2327507
crossref_primary_10_1007_s10147_023_02443_6
crossref_primary_10_1016_S1470_2045_24_00682_X
crossref_primary_10_1186_s12885_024_12745_1
crossref_primary_10_1038_s41375_022_01627_9
crossref_primary_10_1016_j_critrevonc_2023_104085
crossref_primary_10_1080_10428194_2023_2227748
crossref_primary_10_1097_CAD_0000000000001580
crossref_primary_10_3390_jpm12030376
crossref_primary_10_1016_j_ctrv_2023_102651
crossref_primary_10_1056_NEJMra2202672
crossref_primary_10_3389_fonc_2024_1490202
Cites_doi 10.1056/NEJMoa1715519
10.1182/blood-2019-129260
10.1111/bjh.15791
10.1182/blood-2019-124691
10.1182/blood.V124.21.509.509
10.1158/1078-0432.CCR-17-3761
10.1158/1078-0432.ccr-19-3703
10.1038/s41375-019-0575-9
10.1056/NEJMoa1306220
10.1038/s41375-018-0023-2
10.1200/JCO.2016.70.4320
10.1056/NEJMra0904569
10.1200/JCO.2013.54.8800
10.1200/JCO.2021.39.15_suppl.7501
10.1182/blood-2019-126619
10.1016/S0140-6736(15)00667-4
10.1056/NEJMoa1513257
10.1056/NEJMoa1914347
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021. The Author(s).
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021. The Author(s).
– notice: The Author(s) 2021
DBID AAYXX
CITATION
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13045-021-01188-x
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Proquest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE - Academic


CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-8722
EndPage 8
ExternalDocumentID oai_doaj_org_article_5a32b71647d74659993ff91287e58e85
PMC8556975
A681652731
10_1186_s13045_021_01188_x
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: ;
GroupedDBID ---
0R~
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
~8M
PMFND
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c571t-d59f2a40a0a59407427bd42166e4bbe55a11f033325079d937fb2e6132341c2e3
IEDL.DBID M48
ISSN 1756-8722
IngestDate Wed Aug 27 01:24:15 EDT 2025
Thu Aug 21 14:05:06 EDT 2025
Thu Jul 10 23:25:59 EDT 2025
Fri Jul 25 22:03:42 EDT 2025
Tue Jun 17 21:31:40 EDT 2025
Tue Jun 10 20:45:44 EDT 2025
Thu May 22 21:21:20 EDT 2025
Thu Apr 24 23:09:18 EDT 2025
Tue Jul 01 04:23:16 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c571t-d59f2a40a0a59407427bd42166e4bbe55a11f033325079d937fb2e6132341c2e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0001-9748-5486
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13045-021-01188-x
PMID 34717692
PQID 2598999115
PQPubID 54946
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_5a32b71647d74659993ff91287e58e85
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8556975
proquest_miscellaneous_2591210563
proquest_journals_2598999115
gale_infotracmisc_A681652731
gale_infotracacademiconefile_A681652731
gale_healthsolutions_A681652731
crossref_citationtrail_10_1186_s13045_021_01188_x
crossref_primary_10_1186_s13045_021_01188_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-10-30
PublicationDateYYYYMMDD 2021-10-30
PublicationDate_xml – month: 10
  year: 2021
  text: 2021-10-30
  day: 30
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Journal of hematology and oncology
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References ML Wang (1188_CR2) 2013; 369
AF Grajales-Cruz (1188_CR12) 2019; 134
MS Davids (1188_CR10) 2018; 24
M Wang (1188_CR20) 2020; 382
M Dreyling (1188_CR3) 2016; 387
CA Portell (1188_CR8) 2014; 124
M Wang (1188_CR19) 2019; 33
S Rule (1188_CR5) 2019; 134
P Ghia (1188_CR15) 2021; 39
S Rule (1188_CR4) 2018; 32
MS Davids (1188_CR7) 2017; 35
CS Tam (1188_CR16) 2018; 378
1188_CR6
SC Howard (1188_CR13) 2011; 364
1188_CR1
BD Cheson (1188_CR14) 2014; 32
WG Wierda (1188_CR11) 2019; 186
SM Handunnetti (1188_CR17) 2019; 134
Y Song (1188_CR18) 2020; 26
AW Roberts (1188_CR9) 2016; 374
References_xml – volume: 378
  start-page: 1211
  issue: 13
  year: 2018
  ident: 1188_CR16
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1715519
– volume: 134
  start-page: 5484
  issue: 1
  year: 2019
  ident: 1188_CR12
  publication-title: Blood
  doi: 10.1182/blood-2019-129260
– volume: 186
  start-page: 184
  issue: 1
  year: 2019
  ident: 1188_CR11
  publication-title: Br J Haematol
  doi: 10.1111/bjh.15791
– volume: 134
  start-page: 1538
  issue: Supplement_1
  year: 2019
  ident: 1188_CR5
  publication-title: Blood
  doi: 10.1182/blood-2019-124691
– volume: 124
  start-page: 509
  issue: 21
  year: 2014
  ident: 1188_CR8
  publication-title: Blood
  doi: 10.1182/blood.V124.21.509.509
– volume: 24
  start-page: 4371
  issue: 18
  year: 2018
  ident: 1188_CR10
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-3761
– volume: 26
  start-page: 4216
  issue: 16
  year: 2020
  ident: 1188_CR18
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.ccr-19-3703
– volume: 33
  start-page: 2762
  issue: 11
  year: 2019
  ident: 1188_CR19
  publication-title: Leukemia
  doi: 10.1038/s41375-019-0575-9
– volume: 369
  start-page: 507
  issue: 6
  year: 2013
  ident: 1188_CR2
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1306220
– volume: 32
  start-page: 1799
  issue: 8
  year: 2018
  ident: 1188_CR4
  publication-title: Leukemia
  doi: 10.1038/s41375-018-0023-2
– ident: 1188_CR1
– volume: 35
  start-page: 826
  issue: 8
  year: 2017
  ident: 1188_CR7
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.70.4320
– volume: 364
  start-page: 1844
  issue: 19
  year: 2011
  ident: 1188_CR13
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra0904569
– volume: 32
  start-page: 3059
  issue: 27
  year: 2014
  ident: 1188_CR14
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.54.8800
– volume: 39
  start-page: 7501
  issue: 15_suppl
  year: 2021
  ident: 1188_CR15
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2021.39.15_suppl.7501
– volume: 134
  start-page: 756
  issue: Supplement_1
  year: 2019
  ident: 1188_CR17
  publication-title: Blood
  doi: 10.1182/blood-2019-126619
– volume: 387
  start-page: 770
  issue: 10020
  year: 2016
  ident: 1188_CR3
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)00667-4
– volume: 374
  start-page: 311
  issue: 4
  year: 2016
  ident: 1188_CR9
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1513257
– volume: 382
  start-page: 1331
  issue: 14
  year: 2020
  ident: 1188_CR20
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1914347
– ident: 1188_CR6
SSID ssj0061920
Score 2.4582238
Snippet Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The...
Abstract Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Antimitotic agents
Antineoplastic agents
Apoptosis
Blood
Blood cancer
Bone marrow
Cardiac arrhythmia
Creatinine
Development and progression
Hematological cancers/lymphomas
Hematology
Ibrutinib
Inhibitor drugs
Laboratories
Leukemia
Lymphoma
Lysis
Mantle cell lymphoma
Neutropenia
Non-Hodgkin's lymphomas
Oncology
Patients
Potassium
Rapid Communication
Safety
Safety and security measures
Small molecule agents/kinase inhibitors
Targeted cancer therapy
Tumors
Venetoclax
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yB_EifuK4q0YQPEiZps1LOt7GwWUVRgV3YT2FJE3Zgdl2mA-Yue5fvu-lnWGroBevzQuk7_u17_3C2DvIfEF1QBJAVon04BMrXEisBqkt5F7G3pzpN3V2Ib9ewuWdq76oJ6yFB24ZNwSbZ46Sel1qqQDzmbyqRuhVdYAiFBG9FGPevphqfTBVBel-RKZQw5WgH4IJtSPQpGWRbHthKKL1_-mTf--TvBN4Th-xh13GyMftSR-ze6F-wu5Pu3_iT9nNpKl9i7LEsfZFRapnji_mmxUnR7Zu_Nxu-azmNLayWIVyiKdZxmt2dvwaGTsPnD7f8_kOJdtc248ck0K-slVY7_hyUye4t6niw8UVBj2e85-_pj_G518m33mEp33GLk4_n0_Oku5mhcSDFuukhFGVWZna1MJIUnmsXSkzoVSQzgUAK0SV5nmOCZIelZjCVC4LGPkzDHo-C_lzdlQ3dXjBeJBgpValy7WXshTWOulS6SRGXysBBkzsGW18BztOt1_MTSw_CmVa4RgUjonCMdsB-3DYs2hBN_5K_Ynkd6AkwOz4ANXIdGpk_qVGA_aGpG_a6dOD2ZuxKoQikDoxYO8jBRk-voC33fwCsoEgtHqUJz1KNFjfX95rmOkcxspgFVpQri7wJG8Py7STmuDq0GwiDcG9gcoHTPc0s_fu_ZV6dhVBwwsANdLw8n8w65g9yMiWKISnJ-xovdyEV5ibrd3raIa3_jA0Cg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection (ProQuest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NixMxFA-6gngRP3F01QiCBwmdzOQlUy9Si8sqVAV3oZ5CksnsFroztdNCe_UvNy-dVkdhr5MXZibvO3nvF0JeQ-YKzAOYB1Ex4cAxw61nRoFQBnInYm3O5Is8PRefpzDtNtzarqxybxOjoS4bh3vkgxCmFxjMcHi_-Mnw1ig8Xe2u0LhJbiF0GZZ0qekh4cLcIN03yhRy0HI8FmRYlID9lgXb9JxRxOz_3zL_Wy35l_s5uUfudnEjHe0YfZ_c8PUDcnvSnYw_JL_GTe12WEs0ZMBBnOqZpYv5uqVozlaNm5sNndUUm1cWrS8H4WuW8bKdLb0Kyzv3FDfx6Xwb-NtcmXc0hIa0NZVfbelyXbMwt6niw8VlcH00p99_TL6Nzj6Nv9IIUvuInJ98PBufsu5-BeZA8RUrYVhlRqQmNTAUmCQrW4qMS-mFtR7AcF6leZ6HMEkNyxDIVDbzwf9nwfW5zOePyVHd1P4JoV6AEUqWNldOiJIbY4VNhRXBBxsBkBC-X2jtOvBxvANjrmMSUki9Y44OzNGROXqTkLeHOYsd9Ma11B-QfwdKhM2OD5rlhe60UIPJM4sZoiqVkBDkKa-qYXDRykPhi_CZL5H7eteDelB-PZIFlwhVxxPyJlKg-ocfcKbrYgjLgEBaPcrjHmVQW9cf3kuY7sxGq_8IeUJeHYZxJpbC1b5ZRxoEfQOZJ0T1JLP37_2RenYZocMLADlU8PT6lz8jdzLUEnTR6TE5Wi3X_nmIvVb2RVSw380TLSc
  priority: 102
  providerName: ProQuest
Title Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
URI https://www.proquest.com/docview/2598999115
https://www.proquest.com/docview/2591210563
https://pubmed.ncbi.nlm.nih.gov/PMC8556975
https://doaj.org/article/5a32b71647d74659993ff91287e58e85
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swEBddC2MvY58sW5dpMNjD8Brb-nAGY6ShpQukK2sD2ZOQZHkNuHaWOJC87i_fneyEeStjTwbrZGTdne5O0v2OkDc8sgnGAYHjLAuY5TbQoXGBlpxJzWPL_N2c8bk4m7DRlE_3yLbcUTOBy1tDO6wnNVnk79c_Np9A4T96hU_E0TLE474ALxtgHmUSgE95AJZJoqKO2e5UAWOFOkGSC1gFomibRHPrN1qGyuP5_71q_3mT8jfTdPqA3G98SjqoheAh2XPFI3J33JyaPyY_h2VhaxwmCtExiFoxM3Ser5YUl7qqtLle01lBMbFlvnTpEYxm4QvxbOgNTH3uKG7w03wDvC9v9AcKbiNd6sxVG7pYFQH0LTP_cn4NZpHG9PLb-GJw9Xn4hXoA2ydkcnpyNTwLmtoLgeUyrIKU97NIs57uad5nGEBLk7IoFMIxYxznOgyzXhzH4ELJfgpOTmYiB75BBGbRRi5-SvaLsnDPCHWMayZFamJpGUtDrQ0zPWYY2GfNOO-QcDvRyjbA5FgfI1c-QEmEqpmjgDnKM0etO-Tdrs-8huX4J_Ux8m9HiZDa_kW5-K4aDVVcx5HB6FGmkgkOjnOcZX0w39LxxCUwzFfIfVXnp-4WBjUQSSgQxi7skLeeAoUVfsDqJsMBpgFBtlqUhy1KUGnbbt5KmNpqhII4NUFvPoSRvN41Y0-8Jle4cuVpEBCOi7hDZEsyW__ebilm1x5WPOFc9CV__h9ff0HuRagqaMN7h2S_WqzcS3DOKtMld-RUdsnBYDC6HMHz-OT84mvXb3V0vTb-AlsoOVI
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BqdBLwgrqIwmJFAPKBoudhJioRQVza1bC0TdNL2ZGzHYZW6pDStaF_5IL6Rc5ykEJD2ttf4OLF97vG5EPKS-zpGP8AxnKUO01w70lPGkRFnkeSBZjY2ZzgK-6fs4xk_2yK_6lwYDKusZaIV1Emu8R_5HpjpMRozHn8_--5g1yi8Xa1baJRkcWTWP8BlK94NPgB-X_n-4cG413eqrgKO5pG3cBLeSX3JXOlK3mHoGkYqYb4XhoYpZTiXnpe6QRCAcRB1ElDfqfINaD0fBL72TQDvvUG2WQCuTIts7x-MTj7Xsh-9EbdOzYnDvcLDi0gHwyAwwzN2Vg31Z7sE_K8L_o3P_EvhHd4ldypLlXZL0rpHtkx2n9wcVnfxD8jPXp7psroTBZ8bCDibKDqbLguKAnSR66lc0UlGMV1mVphkD1Yzt-191vQSEDo1FK8N6HQNFJVfyrcUjFFayNQs1nS-zByYm6f24ewClC0N6Jfz4Ul3POh9orYs7kNyei1n_4i0sjwzjwk1jEsWhYkKIs1Y4kmpmHKZYqD1JeO8Tbz6oIWuyp1j142psG5PHIoSOQKQIyxyxKpN3mzmzMpiH1dC7yP-NpBYqNs-yOffRMX3gsvAV-iTRknEQg4UHKRpB4yCyPDYxLDMXcS-KLNeN-JGdMPYC7E4ntcmry0EChzYgJZV3gQcA5buakDuNCBBUOjmcE1hohJUhfjDVm3yYjOMMzH4LjP50sJgmTkeBm0SNSizsffmSDa5sMXKY87DTsSfXP3xXXKrPx4ei-PB6Ogpue0jx6CB4O6Q1mK-NM_A8luo5xW7UfL1ujn8N59baRY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Concurrent+ibrutinib+plus+venetoclax+in+relapsed%2Frefractory+mantle+cell+lymphoma%3A+the+safety+run-in+of+the+phase+3+SYMPATICO+study&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Wang%2C+Michael&rft.au=Ramchandren%2C+Radhakrishnan&rft.au=Chen%2C+Robert&rft.au=Karlin%2C+Lionel&rft.date=2021-10-30&rft.issn=1756-8722&rft.eissn=1756-8722&rft.volume=14&rft.issue=1&rft.spage=179&rft_id=info:doi/10.1186%2Fs13045-021-01188-x&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon